^
Association details:
| Biomarker: | MET exon 14 mutation |
|---|---|
| Cancer: | Biliary Tract Cancer |
| Drug Class: | c-MET inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical and genomic analysis of non-small cell lung cancer (NSCLC) patients with MET exon14 skipping (METex14) mutations and responses to anti-MET therapy.
Published date:
05/13/2020
Excerpt:
Genospace enables real-time patient identification of METex14-positive NSCLC cases and analysis of these cases indicates that anti-MET therapy may be effective at any line of treatment.
DOI:
10.1200/JCO.2020.38.15_suppl.9613
Source:
Title:
The landscape of MET mutations in Chinese biliary tract cancers.
Excerpt:
MET mutations were detected in 4.1% of patients with BTCs, including 5.3% in ICC, 3.4% in hilar cholangiocarcinoma (HCCA), 3.0% in ECC, and 2.6% in gallbladder cancer (GBCA). Gene amplification was the most common type of MET mutation in BTC (2.6%) compared with gene rearrangements/fusions (1.1%) and SNV (0.9%). Novel MET fusion partners, including TNS3 and TRIM4, and MET exon 14 skipping mutation, were also detected....MET mutations were detected in 4.5% BTCs, and MET inhibitors may be potential treatment options for BTC patients.
DOI:
10.1200/JCO.2020.38.15_suppl.e16652
Trial ID:
